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Abstract
Background—We evaluated the relationship between florbetapir-F18 positron emission 
tomography (FBP PET) and cerebrospinal fluid (CSF) biomarkers.
Methods—Alzheimer’s Disease Neuroimaging Initiative (ADNI)-GO/2 healthy control (HC), 
mild cognitive impairment (MCI), and Alzheimer’s disease (AD) dementia subjects with clinical 
measures and CSF collected ±90 days of FBP PET data were analyzed using correlation and 
logistic regression.
Results—In HC and MCI subjects, FBP PET anterior and posterior cingulate and composite 
standard uptake value ratios correlated with CSF amyloid beta (Aβ1-42) and tau/Aβ1-42 ratios. 
Using logistic regression, Aβ1-42, total tau (t-tau), phosphorylated tau181P (p-tau), and FBP PET 
composite each differentiated HC versus AD. Aβ1-42 and t-tau distinguished MCI versus AD, 
without additional contribution by FBP PET. Total tau and p-tau added discriminative power to 
FBP PET when classifying HC versus AD.
Conclusion—Based on cross-sectional diagnostic groups, both amyloid and tau measures 
distinguish healthy from demented subjects. Longitudinal analyses are needed.
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1. Background
Hallmark neuropathological lesions of Alzheimer’s disease (AD) at autopsy are amyloid 
beta (Aβ) protein deposition in plaques and hyperphosphorylated tau deposition in 
neurofibrillary tangles [1]. However, data from the National Institute on Aging (NIA) 
Alzheimer’s Disease Centers collected from 2005 to 2010 found ranges for sensitivity of 
70.9% to 87.3% and specificity of 44.3% to 70.8% when clinical diagnoses of possible and 
probable AD dementia are compared with postmortem histopathology diagnosis [2]. 
Florbetapir-F18 positron emission tomography (FBP PET) for estimating beta-amyloid 
neuritic plaque density was Food and Drug Administration (FDA)-approved in April 2012 
and has high sensitivity (96%; 95% CI [confidence interval] 80%–100%) and specificity 
(100%; 95% CI 78%–100%) versus autopsy within 1 year [3]. Another positron emission 
tomography (PET) radiotracer used to quantify amyloid deposits in the brain in research 
settings is Pittsburgh compound B (PiB) [4, 5]. Cerebrospinal fluid (CSF) levels of Aβ1-42, 
total tau (t-tau), and phosphorylated tau181P (p-tau) [6] are additional research tools with 
ongoing efforts to standardize across laboratories and patients [7, 8].
A model of the temporal order in which clinically measurable AD biomarkers become 
abnormal throughout the progression of AD has been proposed by Jack and colleagues [9]. 
According to this model, abnormal CSF Aβ1-42 and amyloid PET findings are detected 
earliest, followed by CSF tau and other biomarker types. Deposition of Aβ into plaques 
appears very early in the disease process during the asymptomatic stages prior to AD 
dementia. In contrast, elevated tau levels are downstream biomarkers that become strikingly 
more abnormal closer to the development of clinical symptoms [9]. Evidence continues to 
accumulate in support of this model [10–12]. Fagan and colleagues reported a similar CSF 
biomarker phenotype in patients with very mild AD symptoms (Clinical Dementia Rating 
[CDR]=0.5) versus patients with more advanced AD (CDR>1) [13].
There is no consensus for antemortem staging of AD clinical phases using biomarker 
thresholds and where the progression of neuropathological changes is hypothesized to be on 
a continuum beginning with a long asymptomatic period and culminating in dementia [14, 
15]. Further, symptom severity is influenced by multiple factors, such as age [16], 
premorbid functioning [17], education [18], cognitive reserve [14], apolipoprotein E epsilon 
4 (APOE4) allele carrier status [19], and certain concurrent medical conditions [20]. Thus, 
there may be a discrepancy between the presence and degree of AD neuropathology with the 
expression of AD symptoms on an individual basis. These challenges underscore the need 
for additional tools, such as AD clinical biomarkers, to aid the accurate diagnosis and 
staging of AD across the continuum of clinical progression [21].
The CSF Aβ1-42 and tau analytes and amyloid PET neuroimaging as adjunctive biomarkers 
for diagnosis of AD are not commonly used in clinical practice but have the potential to 
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significantly impact accuracy of a clinical diagnosis. There is a small amount of emerging 
literature about their relationship to each other across the spectrum of disease progression. 
Studies of the amyloid brain deposits assessed with PiB PET and CSF levels of Aβ1-42 found 
an inverse relationship between them, no relationship between PiB and CSF t-tau or p-tau, 
and discordance with clinical diagnosis where some healthy controls had evidence of 
amyloid positive status by both PiB and CSF Aβ1-42 [4, 5]. Binary classification using PiB 
PET and CSF-Aβ1-42 overlapped in 96.4% [4].
We explored cross-sectional relationships between FBP PET and CSF biomarkers among 
groups of healthy control (HC), mild cognitive impairment (MCI), and AD dementia 
subjects enrolled in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) using 
approaches not previously reported. We measured correlations between regional and 
composite FBP PET values and CSF Aβ1-42, t-tau, and p-tau, and their ratios in diagnostic 
groups. We used logistic regression to compare composite FBP PET values with CSF 
Aβ1-42, t-tau, and p-tau in distinguishing between diagnostic groups including evaluating for 
additive contributions by the other biomarker type.
2. Methods
2.1. Subjects and study design
Data used in the preparation of this article were obtained from the ADNI database 
(adni.loni.usc.edu). The ADNI was launched in 2003 by the NIA, the National Institute of 
Biomedical Imaging and Bioengineering (NIBIB), the FDA, private pharmaceutical 
companies and non-profit organizations, as a $60 million, 5-year public-private partnership. 
The primary goal of ADNI has been to test whether serial magnetic resonance imaging 
(MRI), PET, other biological markers, and clinical and neuropsychological assessment can 
be combined to measure the progression of MCI and early AD. Determination of sensitive 
and specific markers of very early AD progression is intended to aid researchers and 
clinicians to develop new treatments and monitor their effectiveness, as well as lessen the 
time and cost of clinical trials.
The Principal Investigator of this initiative is Michael W. Weiner, MD, VA Medical Center 
and University of California – San Francisco. ADNI is the result of efforts of many co-
investigators from a broad range of academic institutions and private corporations, and 
subjects have been recruited from over 50 sites across the United States and Canada. The 
initial goal of ADNI was to recruit 800 subjects, but ADNI has been followed by ADNI-GO 
and ADNI-2. To date these 3 protocols have recruited over 1500 adults, ages 55 to 90, to 
participate in the research, consisting of cognitively normal older individuals, people with 
early or late MCI, and people with early AD. The follow-up duration of each group is 
specified in the protocols for ADNI-1, ADNI-2, and ADNI-GO. Subjects originally 
recruited for ADNI-1 and ADNI-GO had the option to be followed in ADNI-2. For up-to-
date information, see www.adni-info.org.
Data were downloaded in August 2012 from ADNI-GO/2 which included FBP PET scans. 
Participants were recruited from outpatient memory clinics. Clinical diagnoses were 
assigned to participants by the site investigators and reassessed at each visit. Normal age-
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matched control subjects showed no signs of depression, MCI, or dementia (www.adni-
info.org). Participants with MCI were required to present education-adjusted ranges on the 
Logical Memory II subscale from the Wechsler Memory Scale-Revised: ≥ 16 years of 
education – 9 to 11 for early MCI, ≤ 8 for late MCI; 8 to 15 years of education – 5 to 9 for 
early MCI, ≤4 for late MCI; 0 to 7 years of education – 3 to 6 for early MCI, ≤ 2 for late 
MCI. Additionally, participants with MCI had Mini-Mental State Examination (MMSE) 
scores between 24 and 30 (inclusive), a CDR of 0.5 with a Memory Box score ≥ 0.5, and 
preserved activities of daily living. Participants with AD dementia met the National Institute 
of Neurological and Communicative Disorders and Stroke - Alzheimer’s Disease and 
Related Disorders Association (NINCDS-ADRDA) criteria for probable AD. At subsequent 
visits, diagnoses were categorized as HC, MCI, or AD. For this cross-sectional analysis, we 
selected all HC, MCI, and AD dementia subjects who had clinical measures, diagnoses, and 
CSF analyte levels within ±90 days of their FBP PET scans.
2.2. Clinical measures
The following clinical measures were included to describe the sample: Estimated Verbal 
Intelligence Quotient (EVIQ), Functional Activities Questionnaire (FAQ), Geriatric 
Depression Scale (GDS), Neuropsychiatric Inventory-Questionnaire (NPI-Q), 11- and 13-
item versions of the cognitive subscale of the Alzheimer’s Disease Assessment Scale 
(ADAS-Cog11; ADAS-Cog13), and MMSE.
2.3. Biomarker variables
2.3.1. Florbetapir-F18 positron emission tomography—FBP PET data for all 
subjects were analyzed using a semi-automatic method, which includes spatial normalization 
to a standard template in the Talairach space [3]. Standard uptake value ratios (SUVRs) 
using whole cerebellum as the reference region were calculated for 6 FBP PET regions of 
interest (ROI): posterior cingulate, precuneus, parietal, temporal, anterior cingulate, frontal; 
and the composite, which is their mean SUVR. The 6 target ROIs were defined in a previous 
study,[22] in which PET uptake was increased in AD subjects compared with control 
subjects. Raw FBP PET data were initially pre-processed at the Laboratory of Neuroimaging 
at the University of California, Berkeley (http://resource.loni.ucla.edu/research/data-
interpretation/).
2.3.2. Cerebrospinal fluid measures—Samples were analyzed using the Luminex® 
xMAP® platform (Austin, TX) and Innogenetics/Fujirebio AlzBio3 immunoassay kits 
(Gent, Belgium) by the ADNI Core Laboratory at the University of Pennsylvania Medical 
Center. The following variables were determined: Aβ1-42, t-tau, p-tau, t-tau/Aβ1-42 ratio, and 
p-tau/Aβ1-42 ratio.
2.4. Genotyping
A blood sample for genomic deoxyribonucleic acid extraction was obtained at enrollment 
for all study participants. The APOE4 genotyping on these samples was performed by 
Illumina® (San Diego, CA).
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2.5. Statistical analyses
Pearson correlation coefficients were calculated among 5 CSF and 7 FBP PET variables by 
diagnostic group. Demographic and other clinical characteristics were compared among 3 
diagnostic groups with Chi-square/Fisher’s exact test for categorical characteristics and 
analysis of variance for continuous variables. A significance cutoff of P≤.0014 based on 
Bonferroni correction was applied (i.e., taking into account 35 correlations for each 
diagnostic group).
Logistic regression modeling assessed relationships between clinical diagnosis with CSF 
variables (not ratios) and the FBP PET composite SUVR. The likelihood ratio test was used 
to examine whether adding CSF biomarkers to the model, which regresses clinical diagnosis 
on FBP PET composite SUVR, significantly improved model fit, and vice versa. Analyses 
were adjusted for the following subject demographics: APOE4 carrier status (binary); age at 
FBP PET scan; gender; and EVIQ. Data are expressed with bolded P-value notation for 
analyses meeting the statistical significance threshold after Holm-Bonferroni correction [23] 
for multiple comparisons (i.e., taking into account 30 analyses). All regression analyses 
were done separately for 3 pairs of diagnoses: HC versus MCI, MCI versus AD, and HC 
versus AD. For all analyses, statistical significance was defined as P≤.05, except where 
corrections were applied.
3. Results
3.1. Subject characteristics
A total of 577 subjects underwent FBP PET scans and had clinical diagnoses available 
within ±90 days of the scan. Of these, 344 subjects had all data points available for FBP 
PET, CSF, clinical diagnosis, age, and EVIQ, as well as sex and APOE4 status, and were the 
basis of this analysis. These 344 subjects consisted of 97 HC, 226 MCI, and 21 AD 
dementia subjects; mean ages were 74.5 (±5.6) years in HC, 71.4 (±7.5) years in MCI, and 
74.0 (±10.0) years in AD dementia subjects (Table 1). Neuropsychiatric assessment scale 
scores differed significantly (P ≤.05) among groups, with AD dementia subjects most 
severely affected (Table 1).
3.2. Correlation analyses of biomarker variables by diagnostic group
Pearson’s correlation coefficients were assessed between FBP PET SUVR and CSF 
biomarkers. The highest statistically significant (P≤.05, Bonferroni corrected) correlations 
were between FBP PET anterior cingulate, posterior cingulate, and composite SUVRs with 
CSF Aβ1-42, t-tau/Aβ1-42 ratio, and p-tau/Aβ1-42 ratio for HC and MCI groups (Table 2).
Although significant correlations between CSF tau measures and FBP PET variables were 
seen, the values of the correlation coefficients were relatively lower unless CSF tau was in a 
ratio with Aβ1-42. Correlations between both t-tau and p-tau and several FBP PET variables 
did reach statistical significance in the MCI group. In the AD dementia group, no significant 
correlations were observed (Table 2).
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3.3. Regression analyses of biomarker variables
After Holm-Bonferroni correction, logistic regression modeling of biomarkers found no 
variables that statistically significantly differentiated HC from MCI (Table 3). Amyloid 
biomarkers alone (FBP PET and CSF Aβ1-42) significantly distinguished between diagnostic 
groups when comparing HC and AD dementia groups (FBP PET, P=.0002; CSF Aβ1-42, P=.
0007). CSF t-tau significantly differentiated AD dementia from both HC (P<.0001) and 
MCI groups (P=.0003), and CSF p-tau distinguished between HC and AD dementia groups 
(P=.0001).
Table 3 also shows the effect of adding CSF or FBP PET variables to the other biomarker 
type to assess any additional contribution to differentiating diagnostic groups (where the 
reported P-values represent the impact of just the additional information). No significant 
gain in differentiation was observed when testing FBP PET variables in the presence of CSF 
variables for any group comparison. However, adding CSF t-tau or CSF p-tau to FBP PET 
significantly improved differentiation between HC and AD dementia groups.
4. Discussion
This cross-sectional analysis explored relationships between 2 types of AD biomarkers, 
amyloid PET imaging (FBP PET) and CSF analytes (Aβ1-42, t-tau, and p-tau), for their 
ability to differentiate clinical diagnostic group status among HC, MCI, and AD dementia 
subjects in ADNI. Both amyloid-related biomarkers were highly correlated with each other. 
Overall, the amyloid-related biomarkers were not appreciably different with respect to 
categorical clinical classification in that adding one to the other in logistic regressions did 
not improve classification.
Specifically, in logistic regression analyses, neither CSF Aβ1-42 nor FBP PET distinguished 
HC and MCI, probably because amyloid pathology in those who could later progress to 
clinical AD had already manifested. However, CSF Aβ1-42 and FBP PET each distinguished 
HC from AD groups, as did CSF t-tau and p-tau. Additionally, CSF t-tau also significantly 
differentiated AD dementia from MCI, and CSF p-tau distinguished between HC and AD 
dementia groups.
These findings with CSF tau are consistent with CSF tau abnormalities manifesting later and 
progressively in the disease, as compared to amyloid plaque, which exhibits substantial 
deposition by the time patients present with MCI [9].
CSF Aβ1-42 but not FBP PET significantly distinguished MCI from AD dementia groups; 
however, FBP PET was close to the threshold applied by the Holm-Bonferroni correction 
for the multiple comparisons method, and it is possible that a better-powered study might 
have found a different result. Once a person has positive binary status the rate of amyloid 
SUVR increase is slower during MCI and dementia stages than in the decades before MCI 
[15].
We found a number of statistically significant correlations between the biomarker types, 
especially those that involved beta-amyloid. Although significant correlations between CSF 
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tau measures and FBP PET variables were seen, the values of the correlation coefficients 
were relatively lower unless CSF tau was in a ratio with CSF Aβ1-42.
Within the HC and MCI groups, we found some strong and significant correlations for FBP 
PET with CSF Aβ1-42, with the anterior and posterior cingulate ROIs and composite SUVRs 
being the most notable. This is consistent with the known neuroanatomical progression 
pattern of AD where cingulate gyri are affected early with beta-amyloid plaque. In the AD 
dementia group, the highest correlations were between CSF Aβ1-42 and FBP PET, but no 
correlations reached statistical significance. However, it needs to be considered that the 
sample size for the AD dementia group was much smaller than the other groups.
Interestingly, CSF t-tau provided differentiation in the comparisons of HC versus AD 
dementia and MCI versus AD dementia, but not HC versus MCI. This suggests that 
amyloid-related biomarkers are informative as adjunctive tests for establishing an AD 
diagnosis since the associated pathology starts long before clinical symptoms appear, while 
tau may be more helpful for staging because it accumulates in the later stages of the disease, 
as has been described previously. While CSF Aβ1-42 changes are observed 5 to 10 years 
before conversion of MCI to AD dementia, CSF t-tau and p-tau seem to be markers of later 
stage pathology [24]. Thomann and colleagues associated changes in CSF t-tau and p-tau 
with neurodegenerative changes in MCI subjects who converted to early AD dementia [25]. 
Alternatively, some studies have suggested that tau abnormalities at the cellular level may 
begin in the asymptomatic period before or simultaneously with amyloid [26], but our 
current clinical biomarker methodologies may not be targeted or sensitive enough to detect 
those [27].
Doré and colleagues recently described longitudinal (18- and 36-months) relationships 
among Aβ deposition, cortical thickness, and memory [28]. They reported a faster rate of 
gray matter atrophy in the temporal cortex and hippocampi and greater episodic memory 
impairment in clinically unimpaired individuals who were amyloid positive on PiB PET 
than those who were amyloid negative [28]. A longitudinal study published by the 
Australian Imaging Biomarkers and Lifestyle (AIBL) research group estimated that it takes 
19.2 years (95% CI 16.8–22.5) for subjects to progress from the threshold of PiB PET 
positivity to amyloid levels observed in AD dementia [15]. After the emergence of 
symptoms of AD, the rate of Aβ deposition slowed and then plateaued at the dementia stage 
[15]. Additionally, a study of 401 ADNI subjects found that reduction in the CSF Aβ1-42 
level becomes dynamic early, whereas changes in CSF t-tau levels and adjusted 
hippocampal volumes occur later and may be biomarkers of downstream pathophysiological 
processes [29]. However, a study by Driscoll and colleagues in non-demented individuals 
did not observe a correlation between the level of amyloid load and longitudinal brain 
volume changes [30].
The generalizability of our results to the broader population is uncertain and potentially 
limited by the study sample. We used data from ADNI-GO and ADNI-2 cohorts, which 
represents a selected convenience sample including subjects with amnestic MCI, but also 
higher education and cognitive reserve. Compared to the ADNI cohort, the population-based 
sample in the Mayo Clinic Study of Aging (MCSA) [31] was older and less educated, and 
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had lower MMSE scores and less frequent family history of AD. The rate of hippocampal 
volume decline was larger in ADNI subjects compared with MCSA, suggesting more 
advanced brain pathology in ADNI subjects [31]. Additionally, analyzing early and late 
MCI subjects as 1 group might have affected our findings. Further, because ADNI used a 
central laboratory to test CSF, the lack of standardization of CSF AD biomarker 
measurements across clinical sites and assays may limit the applicability of our results to 
clinical practice. Finally, the analyses presented here are based on cross-sectional and not 
longitudinal data. Prospective, longitudinal studies are needed to confirm or refute our 
findings. The strengths of our study are the relatively large HC and MCI sample sizes and 
the combination of CSF and FBP PET measures where most prior work was reported using 
PiB PET.
In conclusion, we found some unique characteristics, but also considerable overlap between 
CSF and FBP PET measures when assessing their ability to distinguish among pairs of HC, 
MCI, and AD dementia groups. We report both composite and ROI correlations for FBP 
PET with CSF. Our findings of differences in differentiation of AD stages by amyloid 
versus tau biomarkers might aid in the development of further diagnostic and staging tools 
for AD.
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GDS Geriatric Depression Scale
HC healthy control
MCI mild cognitive impairment
MCSA Mayo Clinic Study of Aging
MMSE Mini-Mental State Examination
MRI magnetic resonance imaging
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Research in Context
Systematic Review
The authors reviewed the currently available literature on florbetapir positron emission 
tomography and cerebrospinal fluid biomarkers in Alzheimer’s Disease and combined 
their findings with their clinical experience in this patient population.
Interpretation
The authors found some unique characteristics but also considerable overlap between 
cerebrospinal fluid and florbetapir positron emission tomography measures when 
assessing their ability to distinguish among pairs of healthy control, mild cognitive 
impairment, and Alzheimer’s Disease groups using a variety of analytic methods. These 
findings of differences in differentiation of Alzheimer’s disease stages by amyloid versus 
tau biomarkers might aid in the development of further diagnostic and staging tools for 
Alzheimer’s Disease.
Future Directions
Prospective, longitudinal studies are needed to confirm the results of the presented 
retrospective cross-sectional analyses.
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